Beyond the Pilot: What Separates CROs Deploying AI at Scale from Those Still Stuck in Experimentation

OVERVIEW

The models are available. The use cases are obvious. So why are most CROs still running the same AI pilots they were running eighteen months ago?

AI in clinical research is moving quickly: from isolated automation into agent-driven workflows that influence protocol design, safety monitoring, medical writing, and operational decision-making. The investment is real. Scaled deployment largely isn’t.

The bottleneck is no longer the technology itself. It’s whether organisations have built the governance, infrastructure, and operating controls required to use AI responsibly in regulated environments - where every output must be explainable, every decision auditable, and accountability clearly defined.

At the same time, cost and productivity pressures continue to rise. CROs are being asked to deliver more, faster, and with greater precision. AI is the obvious lever, but only if it can be deployed in ways that preserve the scientific rigour, compliance standards, and patient trust that clinical research depends on.

This discussion explores what it actually takes to operationalise AI at scale in clinical trials: what separates deployable systems from perpetual pilots, what responsible AI adoption looks like in practice, and how leading organisations are preparing for a future where AI systems increasingly move from assisting to acting.

Discussion Themes

• As AI systems shift from assisting to acting, where should the human remain in the loop - and how will regulators respond?
• Where agentic AI can realistically create value in clinical operations today - and where removing human oversight would create more risk than efficiency
• What governance, observability, and auditability need to look like when AI becomes embedded in GxP-relevant workflows
• How CROs are balancing pressure to move faster with the accountability obligations that come with regulated research